Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchEnsitrelvirEnsitrelvir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Ensitrelvir for COVID-19
3 studies from 37 scientists
1,450 patients in 1 country
Statistically significant lower risk for viral clearance.
3 studies from 2 independent teams (all from the same country) show significant improvements.
COVID-19 Ensitrelvir studies. May 2024. c19early.org
0 0.5 1 1.5+ All studies 26% Hospitalization -1% Recovery 10% Viral clearance 38% RCTs 26% Early 26% Favorsensitrelvir Favorscontrol
Recent:
Nobori.
Ensitrelvir has been officially adopted in 1 country. Submit updates/corrections. Summary.
May 27
Covid Analysis Ensitrelvir for COVID-19: real-time meta analysis of 3 studies
Statistically significant lower risk is seen for viral clearance. 3 studies from 2 independent teams (all from the same country) show significant improvements. Meta analysis using the most serious outcome reported shows 26% [-14̴..
Feb 29
Nobori et al., Antiviral Research, doi:10.1016/j.antiviral.2024.105852 Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2
Mouse study showing protective effects against SARS-CoV-2 infection in aged mice with the 3CL protease inhibitor ensitrelvir. A single subcutaneous dose of ensitrelvir at 64, 96, or 128 mg/kg given 24 hours before a lethal SARS-CoV-2 chal..
Feb 6
Yoshida et al., Research Square, doi:10.21203/rs.3.rs-3899998/v1 Real-world Efficacy of Ensitrelvir in Hospitalized Patients with COVID-19 in Japan: A Retrospective Observational Study
Retrospective 154 hospitalized COVID-19 patients in Japan showing faster viral clearance and shorter hospitalization with ensitrelvir treatment compared to remdesivir or molnupiravir. There was no significant difference for fever resoluti..
Dec 31
2023
Bischof, E., Aging and disease, doi:10.14336/AD.2023.0318 Mitigating COVID-19 Mortality and Morbidity in China's Aging Population: A Focus on Available Medications and Future Developments
Review focusing on 3CL protease inhibitors. First generation inhibitors like paxlovid and simnotrelvir require boosting with ritonavir, which can cause drug-drug interactions and other issues. Second generation inhibitors like ensitrelvir..
Jul 13
2023
Yotsuyanagi et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2023.54991 (date from preprint) Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial
11% faster recovery (p=0.3) and 49% improved viral clearance (p=0.001). RCT 1,821 COVID-19 outpatients in Japan, Vietnam, and South Korea, showing improved viral clearance and improved recovery (significant for patients treated within 3 days of onset) with ensitrelvir. Only 2 hospitalizations were reported, w..
Feb 10
2023
Kuroda et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkad027 Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
In Vitro and animal study comparing nirmatrelvir and ensitrelvir, showing similar efficacy in vitro, and equal or better efficacy of ensitrelvir in vivo (with similar unbound-drug plasma concentrations).
Dec 7
2022
Mukae et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac933 Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
9% improved recovery (p=0.28) and 32% faster viral clearance (p=0.0001). RCT 428 COVID-19 patients in Japan showing faster viral clearance and improved recovery with ensitrelvir.
May 17
2022
Mukae et al., medRxiv, doi:10.1101/2022.05.17.22275027 A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
45% improved viral clearance (p=0.002). RCT 69 patients in in Japan, showing faster viral clearance with ensitrelvir. 5-day ensitrelvir (375mg on day 1 followed by 125 mg daily or 750mg on day 1 followed by 250mg daily).
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit